13-Valent Pneumococcal Polysaccharide Conjugate Vaccine(Sinovac Life Sciences)

A phase 1b clinical trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) developed by Sinovac Life Science Co., Ltd will be conducted in children aged 2 months (42-89 days) and 2 to 5 years. The objective of the study is to evaluate the safety and immunogenicity of Sinovac PCV13. The trial is a randomized, double blinded, positive controlled study.

初步评价科兴中维研制的PCV13在2月龄（最小6周）及以上人群中的安全性和免疫原性。